Abstract
This is the report for professionals interested to grasp the field of
apoptopic drug targets in oncology and at the same time have an extensive R&D
overview of breast- and prostate cancer. This extensive 450+ pages report
compiles and analyzes Apoptosis, the type of death about whose genetically
controlled pathways we know the most, and further gives an in depth analysis
in two key oncology areas; Breast- and Prostate cancer
In the report, BioSeeker reports on 90 unique drug target combinations, each
comprised of a different collection or mix of individually defined targets,
for 114 apoptopic drugs designed for the treatment of 48 different cancer
indications To fuel the scientific and competitive thinking, BioSeeker opens
the gate into the presence and relevance of protein-protein interactions
between identified targets of apoptopic drugs. No less than 452
protein-protein interactions were recognized among 96 of the 119 included
apoptopic drug targets.
This report section by the numbers
- A hundred different tables. Includes more than 1,500 active links to
related resources on the Internet
- 114 apoptopic drugs, under development by 87 investigators, are included,
covering more than 430 developmental projects in cancer
- 119 Unique, in-depth, drug target profiles, highlighting twelve themes
about the drug target, i.e. protein-protein interaction with other apoptopic
drug targets, linked cancer indications, drugs under development, compound
types, presence in the Cancer Genome Project etc.
- 90 Unique drug target combinations of apoptopic drugs
- 452 protein-protein interactions among apoptopic drug targets
- Extensive pathway analysis of drug targets
- In breast cancer we have identified 170 drug candidates in clinical stage
of development and more than 100 companies are involved in the development of
these drugs. As a treatment for breast cancer hormone modifying therapies
together with different chemotherapeutic schedules have been of highest
interest during the last years of progress. A vast amount of new clinical
research data has emerged and several new clinical trials have been initiated
and others generated new results. Protein kinase inhibitors and epothilones
have generated substantial amount of new research data in this field. But,
other strategies seem not successful and we are still waiting new information
regarding their progress.
In prostate cancer we have identified 127 drug candidates in phase II or III
stage of development and more than 85 companies are involved in the
development of these drugs. Two of the most successful strategies are
apoptosis inducers and cell based vaccines. Three out of 10 late stage
candidates are apoptosis inducers. Cell based vaccines has been tried for some
time but has so far failed to generate substantial improvements.
The Breast and Prostate Cancer section highlights
- Thorough examination of status and impact of several novel drugs in
development
- Discussion of the challenges in current and future treatment strategies
- Anticancer pipeline of most companies in the field
Key reasons to read this report
- This report serves as a serious reference for professionals interested in
the development of oncology drug targets and selection/validation of targeting
strategies.
- Explore the strengths and weaknesses associated with compounds in clinical
development. Scientific rationale for most novel therapeutics in breast- and
prostate cancer R&D, and the results of clinical trials to date
- Gain insight into the current challenges and commercial opportunities
associated with breast- and prostate cancer therapy
View Cart
